**Industry Revenue Breakdown:**
- Pharmaceutical Research and Development: 70%
- Biotechnology: 20%
- Licensing Fees and Partnerships: 10%

**TOP 3 Markets:**
- South Korea: 40%
- USA: 35%
- Europe: 15%

Qurient Co., Ltd. generates the majority of its revenue from pharmaceutical research and development, indicating their strong pipeline and innovative approaches in drug development. The domestic market of South Korea remains the largest single market, followed by the USA, which holds a significant share due to high demand for biotechnological solutions and the presence of strategic partnerships. Europe completes the top 3 markets, where partnerships and licensing agreements also play a role.

**Production Sites:** South Korea

Qurient Co., Ltd. is a biopharmaceutical company based in South Korea. The company focuses on the research and development of drugs, particularly in the fields of oncology and infectious diseases. The production of their products mainly takes place in South Korea, where they also conduct their research and development activities.

The company utilizes both its own facilities and partnerships with other companies and research institutions to optimize the manufacturing and development of their products.

**Research and Development:** Increase in R&D spending by 20% (2025)

**Partnerships:** New strategic alliances with international pharmaceutical companies (2025)

Qurient Co., Ltd. is strongly focused on expanding its research and development activities to develop innovative drugs. In 2025, the company increased its R&D spending by 20% to drive the development of new therapies.

In addition, Qurient is relying on strategic partnerships with international pharmaceutical companies to expand market access and strengthen global presence. These alliances are intended not only to accelerate product development but also to facilitate entry into new markets.

Another focus is on diversifying the product portfolio, especially in the areas of oncology and infectious diseases, to ensure long-term sustainable growth.

**Main raw materials:** Pharmaceutical active ingredients, chemicals
**Main importing countries:** USA, Germany, China

Qurient Co., Ltd., a company in the biopharmaceutical industry, mainly imports pharmaceutical active ingredients and special chemicals that are required for the development and manufacturing of their products. These materials are crucial for the research and development of new drugs.

The USA and Germany are significant suppliers due to their advanced pharmaceutical industries and the high quality of the materials provided. China is also considered an important partner, especially for more cost-effective chemical raw materials. This diversification of the sources of supply helps Qurient ensure supply security and optimize costs.

**Market share:** Estimated at 5-7% in the field of biotechnology in South Korea (2026)
**Research and development ratio:** 20% of revenue (2025)
**Patent portfolio:** Over 30 active patents (2026)

Qurient Co., Ltd. has gained a solid competitive advantage through its focus on innovative therapies and a strong patent portfolio. The company invests a significant portion of its revenue in research and development, strengthening its position as an innovator in the biotechnology industry.

Another advantage is the strategic partnership with international pharmaceutical companies, which facilitates access to new markets and accelerates product development. Despite intense competition in the industry, Qurient can maintain a strong market position through its specialization and innovation.

**Institutional Investor Share:** Estimate: 25% (2026)

**Insider Buys/Sells:** No specific data available (2026)

The institutional investor share in Qurient Co., Ltd. is estimated to be around 25%. This is typical for companies listed on the KOSDAQ, as institutional investors often invest in high-growth companies.

Current data on insider buys or sells is not available. Typically, such information can be found in annual reports or with regulatory authorities. It is advisable to consult the latest company announcements or regulatory filings for detailed information.

**Market share of Qurient Co., Ltd.:** Estimated 2-3% (2026)

**Major competitors and their market shares:**
1. **Celltrion Inc.:** 15%
2. **Samsung Biologics:** 12%
3. **Hanmi Pharmaceutical:** 9%
4. **LG Chem:** 7%
5. **SK Biopharmaceuticals:** 5%
6. **GC Pharma:** 4%
7. **Daewoong Pharmaceutical:** 3%
8. **Qurient Co., Ltd.:** 2-3%

**Moat of Qurient Co., Ltd.:** Moderate

Qurient Co., Ltd. is a smaller player in the biopharmaceutical sector with an estimated market share of 2-3%. The company's moat is moderate as it focuses on specialized niche products that, however, must compete in a highly competitive market. Innovation and the ability to develop new drugs are crucial for competitiveness.

In comparison, larger companies like Celltrion and Samsung Biologics have significant moats supported by extensive research and development resources, a strong global presence, and established brands. These factors give them a strategic advantage, enabling them to defend and expand market shares more effectively.

**Revenue Growth:** 8.5% (2025)
**Research and Development Ratio:** 25% of revenue (2025)
**Net Income Growth:** 10.2% (2025)

Qurient Co., Ltd. recorded a revenue growth of 8.5% in 2025, attributed to a successful expansion of its product pipeline and increased market penetration. The company continues to heavily invest in research and development, with an R&D ratio of 25% of revenue, indicating a long-term growth strategy and innovation capability.

The net income growth of 10.2% in 2025 shows that Qurient is not only able to increase its revenues but also improve its profitability. These metrics suggest that Qurient Co., Ltd. has a solid financial foundation and is well positioned to capitalize on future market opportunities.

However, investors should also consider the specific risks in the biotechnology industry, such as regulatory hurdles and dependence on research successes. Overall, Qurient could be an attractive investment for investors interested in long-term growth and willing to accept the industry's volatility.

**Dividend payment:** No dividend (as of 2026)

Qurient Co., Ltd. has not paid any dividends so far. The company primarily focuses on research and development in the field of biotechnology, which is typically associated with high investments and reinvestments.

In the biotechnology industry, it is not uncommon for companies not to pay dividends, as they often invest their financial resources in the development of new products and technologies. Therefore, investors should pay more attention to the potential for share price increases rather than dividend payouts.